Official Injection Sites for GLP-1 Medications According to their FDA-approved prescribing information, GLP-1 medications semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are administered as injections just under the skin (subcutaneous) in three areas: Abdomen avoid the 2 inches (5 cm) directly around the navel Thigh outer/front thigh Upper arm back of the upper arm All four FDA labels (Ozempic 1 , Zepbound 2 , Mounjaro 3 , Wegovy 4 ) explicitly state that patients should rotate injection sites with each dose
An engaged user is defined as a participant who completed the 24-week intervention and took any in-app action during the maintenance phase (weeks 24-65)
This is a one-time investment that pays for itself across multiple protocols
However, GLP-1 behaves
Nowadays, MASLD, as the most prevalent chronic liver disease, has a rising number of patients, and it is at an early stage of liver disease
doi: 10.1056/NEJMoa2206038